The Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a breakthrough in cancer treatment, with global clinical trials showing promising results in end-stage patients
Prime Minister Narendra Modi on Wednesday
gifted the nation with CAR-T Cell Therapy, India’s first indigenous cancer cell
therapy, developed by Indian innovators, during the ongoing Emerging Science,
Technology and Innovation Conclave (ESTIC) 2025. Among these therapies is
NexCAR19, the world’s first humanised CAR-T therapy developed in India by
ImmunoACT, a ground-breaking innovation supported by Department of
Biotechnology (DBT) and Biotechnology Industry Research Assistance Council
(BIRAC).
DBT is promoting
early and late translational research to develop novel and indigenous
CAR-T-based therapeutics to combat various cancers by supporting
interdisciplinary teams to venture into immunotherapeutic solutions for a
broader spectrum of cancers, including both liquid and solid cancers, and ways
to overcome associated toxicities. This includes cancers like multiple myeloma
(MM), refractory or relapsed B-cell acute lymphoblastic leukaemia,
glioblastoma, and others.
No comments:
Post a Comment